Background:

BMS-202 is a potent PD-1/PD-L1 inhibitor, which binds to PD-1 and inhibits human PD-1/PD-L1 interaction, with an IC50 of 18 nM[1].

参考文献:
[1]. Zak KM, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016 May 24;7(21):30323-35.